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Abstract
Peripheral nervous system involvement has been reported in systemic B or T cell lymphoma and may
result from many mechanisms. We present a case of 59-year-old Caucasian man presented with a
three years history of progressively worsening peripheral neuropathy with no obvious reason. An
extensive workup revealed anti-myelin-associated glycoprotein neuropathy as the only presenting
feature of low grade B cell Lymphoma.
Introduction
Peripheral nervous system involvement has been reported
in systemic B or T cell lymphoma and may result from
many mechanisms. Intraneural localization of lymphoma
could result in meningo-radiculopathy or mononeuro-
pathies, or manifest as a sensory-motor polyneuropathy
sometimes mimicking chronic inflammatory demyelinat-
ing polyneuropathy. We report here the case of a patient
with a previously unknown NHL presenting with a
progressive symmetric polyneuropathy found to have
Anti-Myelin-Associated Glycoprotein (Anti MAG) periph-
eral neuropathy. The extensive work up revealed the
diagnosis of low grade B-cell lymphoma.
Case presentation
A 59-year-old Caucasian man presented with a three years
history of progressively increasing pain, parasthesias and
numbness of lower extremities bilaterally. The disease
progressed to painful disabling weakness in lower
extremities and later it involved his arms. There were no
sphincter disturbances or back pain. The patient reports
25 lbs weight loss during this period. Otherwise his past
medical history was unremarkable. He denied any history
of smoking or alcohol intake and there was no significant
family history.
On physical examination, the vital signs were a blood
pressure (BP) of 110/80 mmHg, heart rate (HR) 78/min,
respiratory rate (RR) 20/min and body temperature (T)
36.2ºC. The patient appeared alert and oriented. There
were no lymph nodes palpable. Physical examination of
the chest, abdomen, back and extremities were unremark-
able. Neurological exam revealed evidence of bilateral
lower extremity weakness with motor power 4/5 in distal
muscular group, hypoactive reflexes in four extremities,
along with hypoesthesia and decreased deep sensation.
A work up for peripheral neuropathy revealed normal
TSH, Vitamin B12 and CPK. Monospot test, VDRL, HIV
antibody, P- and C-ANCA, ANA, anti double-stranded
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DNAwere all negative (Table 1). Electromyography (EMG)
of the lower extremities showed axonal neuropathy. MRI
of the spine ruled out cord lesion. CSF examinations
repeatedly showed increased protein levels (80-91 mg/dl)
with slightly increased white cells (<10 mm3) but no
malignant cell identified (Table 2). Serum protein electro-
phoresis (SPEP) with immunofixation revealed IgM Kappa
monoclonal spike. Quantative immunoglobulin analysis
revealed an elevated IgM level at 313 mg/dL (the upper
limit of normal is 230). Anti MAG Ab were over a million.
Bone marrow biopsy and aspiration disclosed low grade
CD20 positive B-cell lymphoma (Figure 1 and 2).
Following the diagnosis of lymphoma patient underwent
therapy with Rituximab with very good response. His
neuropathy symptoms improved and his follow up Anti
MAG Ab level markedly decreased (Table 3).
Discussion
There are many possible causes of peripheral neuropathy.
Lymphoma can affect the peripheral nervous system in
5% of patients [1]. When it does, the diagnosis can be
challenging since many patients present without estab-
lished diagnosis of lymphoma. In lymphoma patients
most peripheral nerve complications are due to non-
Hodgkin’s lymphoma (NHL). NHL can cause neuropathy
by directly compressing or infiltrating nerves or by remote
effects. Neuropathies could present as mononeuropathy or
polyneuropathy, and may resemble an asymmetric mono-
neuropathy multiplex or a generalized disorder such as
chronic inflammatory demyelinating polyradiculoneuro-
pathy. Hodgkin’s lymphoma (HL), by contrast, rarely
infiltrates nerves. More often, HL causes immunological
disorders of the peripheral nervous system such as
Guillain-Barre syndrome.
Approximately 10% of patients with peripheral neuro-
pathy of otherwise unknown etiology have an associated
monoclonal gammopathy. The hematological condition
mainly associated with this entity is MGUS, but other
malignancies may also occur [2,3]. Disorders such as
multiple myeloma, AL amyloidosis, Waldenström’s
macroglobulinemia, osteosclerotic myeloma, and lym-
phoma have been reported [4]. Features which suggest
malignancies include weight loss, rapid progression of the
neuropathy, higher levels of paraprotein (>1 g/l), elevated
levels of beta-2-microglobulin and light chain proteinuria.
The anti-myelin-associated glycoprotein (MAG) neuro-
pathy is a very rare antibody-mediated demyelinating
neuropathy. The clinical picture is characterized by a distal
and symmetric, mostly sensory neuropathy. Monoclonal
immunoglobulin M anti-MAG antibodies are uniquely
found in this condition and are believed to be pathogenic.
Biopsy of nerve tissue from anti-MAG patients, demon-
strates immunoglobulin M deposits at the site of MAG
localization, demyelination and axonal degeneration.
MAG is a Schwann cell-based glycoprotein and has been
Table 1. Laboratory data
TSH 1.3 uU/ml ANA <1/40
CPK 34 mg/dl ANCA Negative
LDH 132 mg/dl HIV Negative
Vit B12 376 pg/ml VDRL Negative
Table 2. CSF finding
WBC 1 cells/mm3 Glucose 58 mg/dl
RBC 1 cells/mm3 Protein 94 mg/dl
Figure 1. Low grade B cell Lymphoma on bone marrow
biopsy (Hematoxylin and Eosin stain).
Figure 2. Low grade B cell Lymphoma CD20 positive on
bone marrow biopsy.
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implicated as a mediator of an outside-in signaling cascade
influencing the cytoskeletal integrity of axons.
Therapy in patients with anti-MAG neuropathy is directed
at reducing the antibody concentration, and depleting
the monoclonal B cells. Therapeutic intervention depends
on the specific clinical syndrome but is generally directed
at removing the autoantibodies, reducing the number
of monoclonal B cells, and interfering with the effector
mechanisms [5]. The recent availability of rituximab, a
monoclonal antibody suppressing B-cell clones, which is
not myelosuppressive and does not cause secondary
malignancies, allows for early targeted intervention [6,7].
Many clinical trials, [8] have shown that in patients with IgM
autoantibody associated peripheral neuropathies; rituximab
treatment is followed by reduced serum concentrations of
IgM, and by improvement in clinical picture [9].
In our patient, a sensorimotor demyelinating neuropathy
was associated with antibodies directed against the
Myelin-Associated Glycoprotein. Therefore, we present a
rare case of a patient with paraproteinemic polyneuro-
pathy who has IgM autoantibodies against Myelin-
Associated Glycoprotein with underlying low grade B-cell
lymphoma. The IgM type of these autoantibodies suggests
that they represent all or part of the paraprotein produced
by lymphoma cells. The patient responded well to
rituximab treatment with significant improvement of his
numbness and moderate improvement of his lower
extremities weakness in three months.
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Table 3. Anti MAG Ab follow up
T0 T6 T12
1/1,102,400 1/200,000 1/25,600
T0 upon diagnosis, T6 and T12 are after 6, 12 months follow up.
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